Estee Lauder revises guidance
This article was originally published in The Rose Sheet
Executive Summary
The Estee Lauder Companies will lower its sales and earnings per share guidance for the second quarter of fiscal 2009 and its full year. Move reflects "the deteriorated global economic conditions during the quarter" and further uncertainty about consumer spending and market conditions in the near future, firm says Jan. 16. Second-quarter sales are now expected to slip 6% from prior-year figures on a constant currency basis; currency exchange rates will lower reported sales 6.5%. Previously Lauder forecasted 2%-3% sales growth. Diluted net earnings per share will be $0.75-$0.82. Lauder says it expects current retail trends to continue in North America for the rest of the fiscal year; meanwhile growth will fall off in Europe, the Middle East and Africa. Firm retains a "cautiously positive" outlook for Asia/Pacific region. New outlook for fiscal 2009 has net sales flat to down 3% on a constant currency basis. Foreign currency translation is expected to depress sales 5%-7%, with diluted net earnings per share between $1.30 and $1.60. CEO William Lauder says firm is taking steps to protect its business during the economic downturn, "including making prudent investments to support our brands while diligently controlling expenses.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.